Pre-made Landogrozumab benchmark antibody ( Whole mAb, anti-MSTN/GDF-8 therapeutic antibody, Anti-GDF8/MSLHP Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-295

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-295 Category Tag

Product Details

Pre-Made Landogrozumab biosimilar, Whole mAb, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Landogrozumab (INN; development code LY2495655) is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.

Products Name (INN Index)

Pre-Made Landogrozumab biosimilar, Whole mAb, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody

INN Name

Landogrozumab

Target

MSTN

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2015

Companies

Eli Lilly

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Cancer,Cachexia,Muscular atrophy,Pancreatic cancer

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

MSTN

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide